Terumo Corp - TRUMY STOCK NEWS

Terumo Health Outcomes (THO) and Medis Medical Imaging have announced a strategic partnership in the United States to enhance cardiovascular care. The collaboration combines THO's ePRISM clinical decision support platform with Medis' Quantitative Flow Ratio (QFR) technology, a non-invasive software for assessing coronary physiology.

The partnership will pilot at selected clinical sites, using real-time electronic health records data. Medis QFR has shown promising results in the FAVOR trials, demonstrating a 34% reduction in major adverse cardiac events compared to standard procedures. The technology has received approval in Japan and is included in the 2024 ESC guidelines with a Class I recommendation.

The PIONEER IV trial, involving 2,540 patients, will evaluate the next-generation QFR technology's integration with THO's ePRISM platform.

Terumo Interventional Systems has launched its R2P NaviCross peripheral support catheter in the U.S., expanding its radial-to-peripheral portfolio. The new 200 cm length catheter features double-braided, stainless-steel construction for enhanced trackability and torque control in complex procedures. This addition complements Terumo's existing R2P portfolio, which includes the Destination Slender guiding sheath, SlenGuide guiding catheter, Misago self-expanding peripheral stent, and other specialized catheters. The device is specifically designed for treating peripheral artery disease (PAD) and critical limb ischemia through radial access procedures.

Terumo Blood and Cell Technologies has completed a meta-analysis demonstrating the effectiveness of automated red blood cell exchange (aRBCX) in improving quality of life for sickle cell disease (SCD) patients. The study, published in Vox Sanguinis, analyzed over two decades of research and showed that aRBCX leads to shorter hospital stays, reduced procedure times, and fewer pain-related hospitalizations.

The research supports patient testimonials about aRBCX's benefits in managing SCD complications. The company's Spectra Optia™ Apheresis System is used to remove sickled cells from patients' blood. The study also highlighted the need for further research on psychosocial aspects of treatment.

Terumo has established Terumo Ventures, a Corporate Venture Capital (CVC) organization within Terumo Americas Holding, aimed at leading the Group's venture investments. Terumo Ventures will invest US$ 75 million over the next five years in early-stage companies in fields like cardiovascular disease, chronic disease treatment, and digital technologies. The CVC operates in global innovation hubs, such as Massachusetts and California.

Since 2013, Terumo has been building relationships with medtech start-ups through investments in venture capital funds in the US and China. The new CVC aims to increase agility in identifying and executing venture investments, accelerating the acquisition of cutting-edge technologies, and developing a robust M&A pipeline.

Aligned with its 5-Year Growth Strategy 'GS26' and long-term vision 'From Devices to Solutions,' Terumo aims to enhance innovation capabilities. This includes a new director position managing innovation-related functions and fostering cross-functional collaboration.

Terumo Cardiovascular announced that the U.S. FDA has granted 510(k) clearance for its CDI OneView Monitoring System. This next-generation platform can measure and display up to 22 key patient parameters during cardiopulmonary bypass surgery, enhancing perfusion safety and patient outcomes. Key new parameters include measured flow (Q), cardiac index (CI), and regional cerebral oxygen saturation (rSO2). The system's modular design allows for flexible configuration to meet clinical needs. Terumo emphasized the system's development was influenced by extensive feedback from global cardiovascular experts and is aimed at reducing complications such as acute kidney injury.

Terumo Blood and Cell Technologies (Terumo BCT) received FDA clearance for the Rika Plasma Donation System with the iNomi Nomogram, a new innovation that allows plasma donors to donate the right amount of plasma based on their individual characteristics. This system aims to increase collection volume without extending collection time, with an average 10% increase in plasma volume collected per donation in less than 35 minutes. Rika is designed for donor comfort and safety, ensuring a seamless and efficient experience for plasma donors and collection center employees. This innovation is expected to enhance patient access to care and support the needs of patients relying on plasma-derived therapies.

Terumo Medical Corporation (TIS) introduces the AZUR HydroPack Peripheral Coil System, a versatile soft coil with hydrogel technology for embolization, offering optimized stability and precise delivery. The coil is FDA-cleared, with a true .018" primary wind and is available in long lengths, making it the longest gel core coil on the market, allowing for flexible sizing and deployment through microcatheters. The hydrogel technology promotes new tissue growth and tight packing, putting the system in a category of its own in the peripheral coil market.

IceCure Medical participated in a cryoablation symposium in Thailand, showcasing its ProSense System. Professor Fukuma, who has performed over 600 procedures with ProSense, praised its effectiveness and minimal side effects. The partnership between IceCure and Terumo Thailand is expected to improve sales momentum. The growing data on ProSense's efficacy supports its use in treating breast, lung, and kidney tumors.

Terumo Medical Corporation announced the final results of its R.A.V.I. study, highlighting the safety and efficacy of radial artery access in embolization procedures for conditions such as uterine fibroids and hypervascular tumors. The study, involving 99 patients across six hospitals, demonstrated a 100% procedural success rate with significant patient benefits, including same-day discharge for 74.7% of participants. Presenting the findings at the SIR 2023 Annual Scientific Meeting, Dr. Guimaraes emphasized the potential of radial access to become the preferred method in various embolization procedures. Terumo continues to innovate in interventional techniques.